{'fraction_non_alphanumeric': 0.020022246941045607, 'fraction_numerical': 0.004449388209121246, 'mean_word_length': 5.818181818181818, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Structural Characterization of the TIL 1383I T Cell Receptor

Using adoptive cell transfer to reintroduce engineered T cells into patients is an exciting new form of cancer immunotherapy. T cells play a central role in adaptive immunity by eliminating virus‐infected and tumor cells. T cell receptors (TCRs) facilitate this by recognizing antigenic peptides presented by major histocompatibility complexes (MHCs), triggering an immune response. While TCRs in gene‐modified T cells can be used for anti‐tumor clinical responses, clinical trials have shown adverse effects attributable to off‐target toxicity, which stems from the inherent cross‐reactivity of a TCR repertoire developed to engage the larger universe of potential peptide antigens. To understand and begin to address this challenge in immunotherapy, elucidation of TCR structural properties and biochemical characteristics is required.